Trial
NCT04984876
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Allergy, Peanut
Intervention
ligelizumab
Why stopped
Study terminated by sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29